Author

Jean-Frédéric Colombel

EFFICACY OF UPADACITINIB FOR MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE BY DISEASE DURATION: A POST HOC ANALYSIS OF PHASE 3 INDUCTION AND MAINTENANCE STUDIES
EFFICACY OF UPADACITINIB FOR MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE BY DISEASE DURATION: A POST HOC ANALYSIS OF PHASE 3 INDUCTION AND MAINTENANCE STUDIES

Jean-Frédéric Colombel  et al.

RISANKIZUMAB VERSUS USTEKINUMAB FOR PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE STUDY
RISANKIZUMAB VERSUS USTEKINUMAB FOR PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE STUDY

Jean-Frédéric Colombel  et al.

EFFECT OF OZANIMOD TREATMENT AND DISCONTINUATION ON ABSOLUTE LYMPHOCYTE COUNT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A PHASE 3 RANDOMIZED TRIAL
EFFECT OF OZANIMOD TREATMENT AND DISCONTINUATION ON ABSOLUTE LYMPHOCYTE COUNT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A PHASE 3 RANDOMIZED TRIAL

Jean-Frédéric Colombel  et al.

RADIOLOGIC EVALUATION OF FILGOTINIB TREATMENT IN PERIANAL FISTULIZING CROHN’S DISEASE USING A NOVEL SCORING SYSTEM
RADIOLOGIC EVALUATION OF FILGOTINIB TREATMENT IN PERIANAL FISTULIZING CROHN’S DISEASE USING A NOVEL SCORING SYSTEM

Jean-Frédéric Colombel  et al.

DISEASE CONTROL AND CHANGES IN INDIVIDUAL TREATMENT OUTCOMES FROM WEEK 14 TO WEEK 52 WITH VEDOLIZUMAB OR ADALIMUMAB IN ULCERATIVE COLITIS: A VARSITY TRIAL POST HOC ANALYSIS
DISEASE CONTROL AND CHANGES IN INDIVIDUAL TREATMENT OUTCOMES FROM WEEK 14 TO WEEK 52 WITH VEDOLIZUMAB OR ADALIMUMAB IN ULCERATIVE COLITIS: A VARSITY TRIAL POST HOC ANALYSIS

Jean-Frédéric Colombel  et al.

SAFETY, PHARMACOKINETICS, AND IMMUNOLOGICAL EFFECTS OF OMILANCOR (BT-11) IN A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PATIENTS WITH ULCERATIVE COLITIS
SAFETY, PHARMACOKINETICS, AND IMMUNOLOGICAL EFFECTS OF OMILANCOR (BT-11) IN A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PATIENTS WITH ULCERATIVE COLITIS

Jean-Frédéric Colombel  et al.

SAFETY, TOLERABILITY AND PHARMACOKINETICS OF NX-13 IN A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 1 STUDY IN NORMAL HEALTHY VOLUNTEERS
SAFETY, TOLERABILITY AND PHARMACOKINETICS OF NX-13 IN A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 1 STUDY IN NORMAL HEALTHY VOLUNTEERS

Jean-Frédéric Colombel  et al.

WEEK 6 CALPROTECTIN BEST PREDICTS LIKELIHOOD OF LONG-TERM ENDOSCOPIC HEALING IN CROHN'S DISEASE: A POST-HOC ANALYSIS OF THE UNITI/IM-UNITI TRIALS
WEEK 6 CALPROTECTIN BEST PREDICTS LIKELIHOOD OF LONG-TERM ENDOSCOPIC HEALING IN CROHN'S DISEASE: A POST-HOC ANALYSIS OF THE UNITI/IM-UNITI TRIALS

Jean-Frédéric Colombel  et al.

PATIENT REPORTED OUTCOME SEVERITY DOES NOT IMPACT ENDOSCOPIC HEALING IN CROHN'S DISEASE: A POST-HOC ANALYSIS OF SONIC
PATIENT REPORTED OUTCOME SEVERITY DOES NOT IMPACT ENDOSCOPIC HEALING IN CROHN'S DISEASE: A POST-HOC ANALYSIS OF SONIC

Jean-Frédéric Colombel  et al.

SACCHAROMYCES CEREVISIAE, CANDIDA ALBICANS AND ADHERENT-INVASIVE ESCHERICHIA COLI (AIEC) INTESTINAL COLONIZATION IS NOT ASSOCIATED WITH ASCA DETECTION IN CROHN´S DISEASE
SACCHAROMYCES CEREVISIAE, CANDIDA ALBICANS AND ADHERENT-INVASIVE ESCHERICHIA COLI (AIEC) INTESTINAL COLONIZATION IS NOT ASSOCIATED WITH ASCA DETECTION IN CROHN´S DISEASE

Jean-Frédéric Colombel  et al.

IMPACT OF RISANKIZUMAB ON INTESTINAL STENOSIS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: POST HOC ANALYSIS OF THE PHASE 3 ADVANCE, MOTIVATE, AND FORTIFY STUDIES
IMPACT OF RISANKIZUMAB ON INTESTINAL STENOSIS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: POST HOC ANALYSIS OF THE PHASE 3 ADVANCE, MOTIVATE, AND FORTIFY STUDIES

Jean-Frédéric Colombel  et al.

CLINICALLY ADJUSTED VERSUS THERAPEUTIC DRUG MONITORING DOSING REGIMENS WITH ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM THE SERENE-CD MAINTENANCE STUDY
CLINICALLY ADJUSTED VERSUS THERAPEUTIC DRUG MONITORING DOSING REGIMENS WITH ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM THE SERENE-CD MAINTENANCE STUDY

Jean-Frédéric Colombel  et al.

RELATIONSHIP BETWEEN HISTO-ENDOSCOPIC MUCOSAL HEALING AND BASELINE CHARACTERISTICS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS RECEIVING FILGOTINIB IN THE PHASE 2B/3 SELECTION STUDY
RELATIONSHIP BETWEEN HISTO-ENDOSCOPIC MUCOSAL HEALING AND BASELINE CHARACTERISTICS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS RECEIVING FILGOTINIB IN THE PHASE 2B/3 SELECTION STUDY

Jean-Frédéric Colombel  et al.

ASSOCIATION OF BASELINE IL-23 PATHWAY-ASSOCIATED GENE EXPRESSION WITH RISANKIZUMAB-INDUCED CLINICAL REMISSION AND ENDOSCOPIC RESPONSE AT WEEK 12 IN CROHN’S DISEASE PATIENTS
ASSOCIATION OF BASELINE IL-23 PATHWAY-ASSOCIATED GENE EXPRESSION WITH RISANKIZUMAB-INDUCED CLINICAL REMISSION AND ENDOSCOPIC RESPONSE AT WEEK 12 IN CROHN’S DISEASE PATIENTS

Jean-Frédéric Colombel  et al.

EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: FINAL RESULTS FROM THE PHASE 3 U-ACHIEVE MAINTENANCE STUDY
EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: FINAL RESULTS FROM THE PHASE 3 U-ACHIEVE MAINTENANCE STUDY

Jean-Frédéric Colombel  et al.

EFFICACY AND SAFETY OF UPADACITINIB AFTER 2 YEARS OF TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: INTERIM RESULTS FROM THE PHASE 3 OPEN-LABEL EXTENSION STUDY (U-ACTIVATE)
EFFICACY AND SAFETY OF UPADACITINIB AFTER 2 YEARS OF TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: INTERIM RESULTS FROM THE PHASE 3 OPEN-LABEL EXTENSION STUDY (U-ACTIVATE)

Jean-Frédéric Colombel  et al.

EFFICACY OF UPADACITINIB ON LUMINAL STENOSIS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: A POST HOC ANALYSIS OF PHASE 3 STUDIES
EFFICACY OF UPADACITINIB ON LUMINAL STENOSIS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: A POST HOC ANALYSIS OF PHASE 3 STUDIES

Jean-Frédéric Colombel  et al.

EFFICACY AND SAFETY OF USTEKINUMAB FOR CROHN'S DISEASE THROUGH 5 YEARS: FINAL RESULTS FROM THE IM-UNITI LONG-TERM EXTENSION
EFFICACY AND SAFETY OF USTEKINUMAB FOR CROHN'S DISEASE THROUGH 5 YEARS: FINAL RESULTS FROM THE IM-UNITI LONG-TERM EXTENSION

Jean-Frédéric Colombel  et al.

IMPACT OF COVID-19 ON PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA FROM AN INTERNATIONAL REGISTRY
IMPACT OF COVID-19 ON PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA FROM AN INTERNATIONAL REGISTRY

Jean-Frédéric Colombel  et al.

AN ADDITIONAL 12 WEEKS OF RISANKIZUMAB THERAPY INDUCES CLINICAL RESPONSE IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO FAILED TO ACHIEVE CLINICAL RESPONSE AFTER AN INITIAL INDUCTION PERIOD: 24-WEEK POOLED ANALYSIS OF TWO PHASE 3 STUDIES
AN ADDITIONAL 12 WEEKS OF RISANKIZUMAB THERAPY INDUCES CLINICAL RESPONSE IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO FAILED TO ACHIEVE CLINICAL RESPONSE AFTER AN INITIAL INDUCTION PERIOD: 24-WEEK POOLED ANALYSIS OF TWO PHASE 3 STUDIES

Jean-Frédéric Colombel  et al.

Item 21 - 40 / 42
1
2
3